Thousands of rheumatologists and health professionals rely on RheumNow for their daily dose of relevant news and information to keep them up-to-date and improve their practice. With the busy practitioner in mind, RheumNow consistently delivers rheumatology news, journal reports, social media highlights, and current opinions/perspectives from topic experts.
As part of its comprehensive meeting coverage, RheumNow’s faculty reporters and videographers are covering the 2018 EULAR Congress in Amsterdam. Coverage includes a combination of feature articles, news, video reports and interviews, speaker quotes, extensive tweeting and on-site photography. This annual meeting content is packaged on RheumNow’s annual meeting microsite: EULAR18.rheumnow.com.
RheumNow maintains all editorial control, and has final say over what is published. Sponsors/advertisers do not approve content or editorial coverage. RheumNow’s 2018 EULAR Congress coverage sponsor is Horizon Pharma.
2019 Faculty/Contributor Bios + Disclosures
Jack Cush, MD: Dr. Cush is the Director of Clinical Rheumatology at the Baylor Research Institute and a Professor of Medicine and Rheumatology at Baylor University Medical Center in Dallas, TX. He is the Executive Editor of RheumNow.com and Co-Editor of the online textbook RheumaKnowledgy.com. Dr. Cush’s research and interests include novel drug development, rheumatoid arthritis, spondyloarthritis, drug safety, pregnancy and Still’s disease/autoinflammatory syndromes. He has published over 140 articles and 2 books in rheumatology. He can be followed on Twitter: @RheumNow. Disclosure: Investigator for – Abbvie, Astra-Zeneca, Genentech, Janssen, Novartis, Pfizer. Consultant/Advisor to Abbvie, Amgen, BMS, Celgene, Genentech, Horizon, Lilly, Novartis, UCB.
David Liew, FRACP: Dr. Liew is in clinical practice at Austin Health, Melbourne, Australia and is also a research fellow in the Department of Clinical Pharmacology and Therapeutics at the same institution. His areas of interest include immune-related adverse events from checkpoint inhibitors and polymyalgia rheumatica. Follow him on Twitter: @drdavidliew.
Janet Pope, MD: Dr. Pope is a Professor of Medicine at Western University, London, Ontario, Canada. She is a rheumatologist and epidemiologist and is Division Head in Rheumatology at St. Joseph’s Hospital, London, Ontario. She has a major interest in scleroderma including membership in the Canadian Scleroderma Research Group, Scleroderma Clinical Trials Consortium and co-leading the new ACR/EULAR guidelines for SSc, and has published over 250 peer reviewed articles. She was named the Canadian Rheumatology Association Distinguished Investigator in 2013 and Rheumatologist of the Year from the Ontario Rheumatology Association. She supervises students at all levels and runs two nationwide studentships for medical students to be exposed to clinical rheumatology or research in rheumatology.Disclosure: Consulting: AbbVie, Actelion, Amgen, Bayer, BMS, Hospira, Janssen, Lilly, Merck, Novartis, Pfizer, Roche, Sanofi, Sandoz, UCB. Research Grants: Amgen, Bayer, BMS, Merck, Pfizer, Roche, SeaGen, UCB.
Douglas White, MD, PhD: Dr. White studied CD8 T cell biology at the University of Iowa before residency training at UT-Southwestern followed by a rheumatology fellowship and a virology post-doc at Washington University in St. Louis. He currently sees patients at Gundersen Health System in La Crosse, WI, oversees a herpesvirus mutagenesis lab and volunteers for the ACR. Disclosure: Nothing to disclose.